Novartis response to NICE Appraisal Consultation Document (ACD) for Aimovig® (erenumab) for the prevention of migraine
Statement from Haseeb Ahmad, Country President of Novartis UK and Managing Director (UK & Ireland) of Novartis Pharmaceuticals:
“We’re disappointed by this initial decision from the National Institute for Health and Care Excellence (NICE) to not recommend Aimovig® (erenumab) for routine use on the NHS, yet welcome the opportunity to further discuss our submission. If this decision remains unchanged patients will be denied access to the first licensed treatment specifically designed to prevent migraine in adults.
Many migraine patients remain dissatisfied with their current treatment options and have been waiting years for new developments., NICE has recognised the clinical-effectiveness of Aimovig and that a significant unmet treatment need exists for people living with migraine in the UK. Our priority now is to continue working closely with NICE to address any outstanding questions they have in order to secure access to this innovative treatment for anyone that could benefit from Aimovig, as quickly as possible.
NICE does not consider the impact of diseases on broader society when evaluating the cost-effectiveness of medicines. We believe this fails to capture the true value of medicines like Aimovig. As migraine predominantly affects people of working age, it costs the UK economy £8.8 billion per year in lost productivity alone.
There are also important quality of life benefits for patients that must be considered. Unlike Botulinum toxin type A (Botox), Aimovig can be self-administered at home, and does not require repeated clinic visits or multiple injections into the head and neck.”